Advertisement

Onkologische Grundlagen und Molekulargenetik von ZNS-Tumoren im Kindes- und Jugendalter

  • D. Sturm
  • S. M. Pfister
  • H. Witt
Chapter

Zusammenfassung

Das Auftreten von Hirntumoren im Kindes- und Jugendalter ist eng mit der Entwicklung des Zentralnervensystems verknüpft, während der viele unterschiedliche Zellpopulationen über einen gewissen Zeitraum anfällig für tumorauslösende Veränderungen sein können. Dies spiegelt sich in der enormen Vielfalt von Tumorarten wider, von denen einige häufiger, andere sehr selten auftreten und die oft eine umschriebene Altersgruppe betreffen. Das Spektrum reicht von benignen, langsam wachsenden bis hin zu hochgradig aggressiven Tumoren. Die Unterscheidung erfolgt bislang hauptsächlich nach dem histopathologischen Erscheinungsbild der Tumorzellen. In vielen dieser Tumorarten finden sich charakteristische genetische und epigenetische Veränderungen, die zunehmend Einzug in die Klassifikation finden, Aussagen über den Krankheitsverlauf zulassen und zielgerichtete Therapiestrategien ermöglichen. Die derzeitige Behandlung besteht in den meisten Fällen in der operativen Tumorentfernung und einer Kombination von adjuvanter Strahlen- und Chemotherapie.

Literatur

  1. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B (1999) Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 59:74–79PubMedGoogle Scholar
  2. Cage TA, Clark AJ, Aranda D, Gupta N, Sun PP, Parsa AT, Auguste KI (2013) A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas. J Neurosurg Pediat 11:673–681CrossRefGoogle Scholar
  3. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S et al. (2011) Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical pathologic and molecular variables. J Clin Oncol 29:1400–1407CrossRefGoogle Scholar
  4. Gajjar AJ, Robinson GW (2014) Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol 11:714–722CrossRefGoogle Scholar
  5. Gajjar A, Stewart CF, Ellison DW, Kaste S, Kun LE, Packer RJ, Goldman S, Chintagumpala M, Wallace D, Takebe N et al. (2013) Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res 19:6305–6312CrossRefGoogle Scholar
  6. Gajjar A, Bowers DC, Karajannis MA, Leary S, Witt H, Gottardo NG (2015) Pediatric Brain Tumors: Innovative Genomic Information Is Transforming the Diagnostic and Clinical Landscape. J Clin Oncol 33:2986–2998CrossRefGoogle Scholar
  7. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stutz AM et al. (2012) Dissecting the genomic complexity underlying medulloblastoma. Nature 488:100–105CrossRefGoogle Scholar
  8. Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA et al. (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927–932CrossRefGoogle Scholar
  9. Judkins AR, Mauger J, Ht, A, Rorke LB, Biegel JA (2004) Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am J Surg Pathol 28:644–650CrossRefGoogle Scholar
  10. Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T, Mauguen A, Varlet P, Le Deley MC, Lowe J et al. (2012) Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children's Cancer Leukaemia Group (CCLG), Societe Francaise d'Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res 18:2001–2011CrossRefGoogle Scholar
  11. Kool M, Jones DT, Jager N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M et al. (2014) Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25:393–405CrossRefGoogle Scholar
  12. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ryzhova M, Milde T, Bender S, Wittmann A, Schottler A et al. (2010) Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol 28:3182–3190CrossRefGoogle Scholar
  13. Korshunov A, Sturm D, Ryzhova M, Hovestadt V, Gessi M, Jones DT, Remke M, Northcott P, Perry A, Picard D et al. (2014) Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol 128:279–289CrossRefGoogle Scholar
  14. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO Classification of tumors of the central nervous system. IARC, LyonGoogle Scholar
  15. Mack SC, Witt H, Piro RM, Gu, L, Zuyderduyn S, Stutz AM, Wang X, Gallo M, Garzia L, Zayne K et al. (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506:445–450CrossRefGoogle Scholar
  16. Merchant TE, Li, C, Xiong X, Kun LE, Boop FA, Sanford RA (2009) Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. The Lancet Oncology 10:258–266CrossRefGoogle Scholar
  17. Morfouace M, Shelat A, Jacus M, Freeman BB, 3rd, Turner D, Robinson S, Zindy F, Wang YD, Finkelstein D, Ayrault O et al. (2014) Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer cell 25:516–529CrossRefGoogle Scholar
  18. Northcott PA, Lee C, Zichner T, Stutz AM, Erkek S, Kawauchi D, Shih DJ, Hovestadt V, Zapatka M, Sturm D et al. (2014) Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 511:428–434CrossRefGoogle Scholar
  19. Northcott PA, Pfister SM, Jones DT (2015) Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. Lancet Oncol 16:e293–302CrossRefGoogle Scholar
  20. Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. Neuro Oncol 18 (Suppl 5): v1–v75. https://doi.org/10.1093/neuonc/now207CrossRefPubMedGoogle Scholar
  21. Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P et al. (2015) Molecular Classification of Ependymal Tumors across All CNS Compartments Histopathological Grades and Age Groups. Cancer Cell 27:728–743CrossRefGoogle Scholar
  22. Parker M, Mohankumar KM, Punchihewa C, Weinlich R, Dalton JD, Li, Y, Lee R, Tatevossian RG, Phoenix TN, Thiruvenkatam R et al. (2014) C11orf95–RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature 506:451–455CrossRefGoogle Scholar
  23. Pejavar S, Polley MY, Rosenberg-Wohl S, Chennupati S, Prados MD, Berger MS, Banerjee A, Gupta N, Haas-Kogan D (2012) Pediatric intracranial ependymoma: the roles of surgery radiation and chemotherapy. J Neurooncol 106:367–375CrossRefGoogle Scholar
  24. Purdy E, Johnston DL, Bartels U, Fryer C, Carret AS, Crooks B, Eisenstat DD, Lafay-Cousin L, Larouche V, Wilson B et al. (2014) Ependymoma in children under the age of 3 years: a report from the Canadian Pediatric Brain Tumour Consortium. J Neurooncol 117:359–364CrossRefGoogle Scholar
  25. Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J, Jager N, Remke M, Shih D, Northcott PA et al. (2012) Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148:59–71CrossRefGoogle Scholar
  26. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu, L, Holcomb T, Stinson J, Gould SE, Coleman B et al. (2009) Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 361:1173–1178CrossRefGoogle Scholar
  27. Schwartzentruber J, Korshunov A, Liu XY, Jones DTW Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231CrossRefGoogle Scholar
  28. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S et al. (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437CrossRefGoogle Scholar
  29. Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW Capper D, Sill M, Buchhalter I, Northcott PA, Leis I et al. (2016) New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 164(5):1060–1072CrossRefGoogle Scholar
  30. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A et al. (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol123:465–472Google Scholar
  31. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O (1998) Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394:203–206CrossRefGoogle Scholar
  32. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M et al. (2011) Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 20:143–157CrossRefGoogle Scholar
  33. Wu, G, Broniscer A, McEachron TA, Lu, C, Paugh BS, Becksfort J, Qu, C, Ding L, Huether R, Parker M et al. (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253Google Scholar
  34. Zhang J, Wu, G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I et al. (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602–612CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  1. 1.Abteilung Pädiatrische Neuroonkologie, Molekulare DiagnostikDeutsches KrebsforschungszentrumHeidelbergDeutschland
  2. 2.Pädiatrische Neuroonkologie, Deutsches KrebsforschungszentrumUniversitätsklinikum HeidelbergHeidelbergDeutschland
  3. 3.Abteilung Pädiatrische NeuroonkologieDeutsches KrebsforschungszentrumHeidelbergDeutschland

Personalised recommendations